» Articles » PMID: 21097803

Definition of Remission and Relapse in Polymyalgia Rheumatica: Data from a Literature Search Compared with a Delphi-based Expert Consensus

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2010 Nov 25
PMID 21097803
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare current definitions of remission and relapse in polymyalgia rheumatica (PMR) with items resulting from a Delphi-based expert consensus.

Methods: Relevant studies including definitions of PMR remission and relapse were identified by literature search in PubMed. The questionnaire used for the Delphi survey included clinical (n=33), laboratory (n=54) and imaging (n=7) parameters retrieved from a literature search. Each item was assessed for importance and availability/practicability, and limits were considered for metric parameters. Consensus was defined by an agreement rate of ≥80%.

Results: Out of 6031 articles screened, definitions of PMR remission and relapse were available in 18 and 34 studies, respectively. Parameters used to define remission and/or relapse included history and clinical assessment of pain and synovitis, constitutional symptoms, morning stiffness (MS), physician's global assessment, headache, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood count, fibrinogen and/or corticosteroid therapy. In the Delphi exercise a consensus was obtained on the following parameters deemed essential for definitions of remission and relapse: patient's pain assessment, MS, ESR, CRP, shoulder and hip pain on clinical examination, limitation of upper limb elevation, and assessment of corticosteroid dose required to control symptoms.

Conclusions: Assessment of patient's pain, MS, ESR, CRP, shoulder pain/limitation on clinical examination and corticosteroid dose are considered to be important in current available definitions of PMR remission and relapse and the present expert consensus. The high relevance of clinical assessment of hips was unique to this study and may improve specificity and sensitivity of definitions for remission and relapse in PMR.

Citing Articles

Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.

Garcia-Porrua C, Heras-Recuero E, Blazquez-Sanchez T, Torres-Rosello A, Castaneda S, Gonzalez-Gay M J Clin Med. 2024; 13(21).

PMID: 39518631 PMC: 11546695. DOI: 10.3390/jcm13216492.


Polymyalgia rheumatica: An update (Review).

Florescu M, Bobirca F, Florescu A, Padureanu V, Bobirca A, Ciurea P Exp Ther Med. 2023; 26(6):543.

PMID: 37928511 PMC: 10623218. DOI: 10.3892/etm.2023.12242.


Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.

McDowell P, McDowell R, Busby J, Eastwood M, Patel P, Jackson D Eur Respir J. 2023; 62(6).

PMID: 37857423 PMC: 10719453. DOI: 10.1183/13993003.00819-2023.


[Methods for assessment of disease activity of polymyalgia rheumatica].

Reisch M, Dejaco C Z Rheumatol. 2023; 82(5):368-379.

PMID: 37184675 PMC: 10264268. DOI: 10.1007/s00393-023-01358-x.


New-onset giant cell arteritis with lower ESR and CRP level carries a similar ischemic risk to other forms of the disease but has an excellent late prognosis: a case-control study.

Liozon E, Parreau S, Dumonteil S, Gondran G, Bezanahary H, Ly K Rheumatol Int. 2023; 43(7):1323-1331.

PMID: 37024620 DOI: 10.1007/s00296-023-05299-1.


References
1.
Hachulla E, Saile R, Parra H, Hatron P, Gosset D, Fruchart J . Serum amyloid A concentrations in giant-cell arteritis and polymyalgia rheumatica: a useful test in the management of the disease. Clin Exp Rheumatol. 1991; 9(2):157-63. View

2.
Binard A, De Bandt M, Berthelot J, Saraux A . Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum. 2008; 59(2):263-9. DOI: 10.1002/art.23338. View

3.
Myklebust G, Gran J . Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol. 2001; 30(5):260-7. DOI: 10.1080/030097401753180327. View

4.
Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E . Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996; 23(4):624-8. View

5.
Feinberg H, Sherman J, Schrepferman C, Dietzen C, Feinberg G . The use of methotrexate in polymyalgia rheumatica. J Rheumatol. 1996; 23(9):1550-2. View